Citation
Mizusawa, Noriko, et al. "Genetic Analyses in Patients With Familial Isolated Hyperparathyroidism and Hyperparathyroidism-jaw Tumour Syndrome." Clinical Endocrinology, vol. 65, no. 1, 2006, pp. 9-16.
Mizusawa N, Uchino S, Iwata T, et al. Genetic analyses in patients with familial isolated hyperparathyroidism and hyperparathyroidism-jaw tumour syndrome. Clin Endocrinol (Oxf). 2006;65(1):9-16.
Mizusawa, N., Uchino, S., Iwata, T., Tsuyuguchi, M., Suzuki, Y., Mizukoshi, T., Yamashita, Y., Sakurai, A., Suzuki, S., Beniko, M., Tahara, H., Fujisawa, M., Kamata, N., Fujisawa, K., Yashiro, T., Nagao, D., Golam, H. M., Sano, T., Noguchi, S., & Yoshimoto, K. (2006). Genetic analyses in patients with familial isolated hyperparathyroidism and hyperparathyroidism-jaw tumour syndrome. Clinical Endocrinology, 65(1), 9-16.
Mizusawa N, et al. Genetic Analyses in Patients With Familial Isolated Hyperparathyroidism and Hyperparathyroidism-jaw Tumour Syndrome. Clin Endocrinol (Oxf). 2006;65(1):9-16. PubMed PMID: 16817812.
TY - JOUR
T1 - Genetic analyses in patients with familial isolated hyperparathyroidism and hyperparathyroidism-jaw tumour syndrome.
AU - Mizusawa,Noriko,
AU - Uchino,Shinya,
AU - Iwata,Takeo,
AU - Tsuyuguchi,Masaru,
AU - Suzuki,Yasuyo,
AU - Mizukoshi,Tsunenori,
AU - Yamashita,Yoshio,
AU - Sakurai,Akihiro,
AU - Suzuki,Shinichi,
AU - Beniko,Mutsuo,
AU - Tahara,Hideki,
AU - Fujisawa,Masato,
AU - Kamata,Nobuyuki,
AU - Fujisawa,Kenji,
AU - Yashiro,Tohru,
AU - Nagao,Daisuke,
AU - Golam,Hossain Md,
AU - Sano,Toshiaki,
AU - Noguchi,Shiro,
AU - Yoshimoto,Katsuhiko,
PY - 2006/7/5/pubmed
PY - 2007/2/17/medline
PY - 2006/7/5/entrez
SP - 9
EP - 16
JF - Clinical endocrinology
JO - Clin Endocrinol (Oxf)
VL - 65
IS - 1
N2 - BACKGROUND: A subset of familial isolated primary hyperparathyroidism (FIHP) is a variant of hyperparathyroidism-jaw tumour syndrome (HPT-JT). AIM/PATIENTS AND METHODS: We investigated the involvement of the HRPT2, MEN1 and CASR genes in 11 provisional FIHP families and two HPT-JT families. RESULTS: Germline mutations of HRPT2 were found in two of the 11 FIHP families and one of the two HPT-JT families. One FIHP family with parathyroid carcinoma and atypical adenomas and another FIHP family with cystic parathyroid adenoma had novel frameshift mutations of 518-521del and 62-66del, respectively. In a patient with HPT-JT, a de novo germline mutation of 39delC was detected. Novel somatic HRPT2 mutations of 70-73del and 95-102del were found in two of five parathyroid tumours in a family with a 518-521del mutation. Biallelic inactivation of HRPT2 by a combination of germline and somatic mutation was confirmed in the parathyroid tumours. The finding that two families diagnosed with FIHP carried HRPT2 mutations suggests that they have occult HPT-JT. In the remaining 10 families, one family had a missense MEN1 mutation. No mutations of CASR were detected. CONCLUSION: Our results confirm the need to test for HRPT2 in FIHP families, especially those with parathyroid carcinomas, atypical adenomas or adenomas with cystic change.
SN - 0300-0664
UR - https://www.unboundmedicine.com/medline/citation/16817812/Genetic_analyses_in_patients_with_familial_isolated_hyperparathyroidism_and_hyperparathyroidism_jaw_tumour_syndrome_
L2 - https://doi.org/10.1111/j.1365-2265.2006.02534.x
DB - PRIME
DP - Unbound Medicine
ER -